摘要
背景 肺移植中可产生缺血/再灌注损伤(ischemia/reperfusion injury,I/RI),主要以非特异性肺泡损伤、肺水肿、增加的肺血管阻力和缺氧为特征,并最终致移植物功能延迟恢复和移植器官失功. 目的 RNA干扰(RNA interfering,RNAi)基因沉默的进程可通过小分子干扰RNA(small interfering RNA,siRNA)开发出来,从而介导靶向细胞功能的精确控制,为改善肺I/RI提供新思路. 内容 回顾RNAi的发现及相关机制,同时对RNAi技术在肺I/RI模型的应用作一综述,并简介其应用于其他器官I/RI模型靶向治疗的案例. 趋向 基于RNAi的治疗学是一项新型且很有前景的策略,其在改善器官移植的I/RI动物模型的应用将愈将成熟,未来RNAi技术将会成功应用于肺移植的临床治疗.
Background Ischemia/reperfusion-induced lung injury is characterized by non-specific alveolar damage,lung edema,and hypoxemia after lung transplantation,ultimately cause delayed graft function and primary graft dysfunction.Objective The process of gene silencing may be exploited by the use of small interfering RNA (siRNA) to mediate precise control of targeted cellular functions,which could provide a new strategy to improve lung I/RI.Content This review will focus on the current concepts in RNAi,and provide an overview of its application in lung I/RI and the target therapy to other organ after I/RI.Trend The therapeutics based on RNAi is a new and promising strategy,which may improve I/RI of organ transplantation and he RNAi therapy in lung transplant will apply to clinical treatment in the future.
出处
《国际麻醉学与复苏杂志》
CAS
2013年第6期524-527,共4页
International Journal of Anesthesiology and Resuscitation